MX2021002749A - Proteínas de unión al antígeno anti-flt3 mejoradas. - Google Patents
Proteínas de unión al antígeno anti-flt3 mejoradas.Info
- Publication number
- MX2021002749A MX2021002749A MX2021002749A MX2021002749A MX2021002749A MX 2021002749 A MX2021002749 A MX 2021002749A MX 2021002749 A MX2021002749 A MX 2021002749A MX 2021002749 A MX2021002749 A MX 2021002749A MX 2021002749 A MX2021002749 A MX 2021002749A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- flt
- antigen binding
- antibodies
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención proporciona nuevas proteínas de unión al antígeno de tirosina cinasa 3 relacionadas con fms ("FLT3", por sus siglas en inglés) humanas, tales como anticuerpos, que tienen una afinidad de unión a FLT3 y/o actividad antitumoral mejoradas. Los anticuerpos FLT3 de la invención se generaron mediante mutación de un anticuerpo FLT3 parental y se probaron in vitro en ensayos de unión, así como in vivo en un modelo tumoral de ratón y en muestras de tumor de paciente humano. Los anticuerpos de la invención se proporcionan como construcciones monoespecíficas o en un formato de anticuerpo FLT3xCD3 biespecífico y muestran una excelente afinidad por el objetivo y/o destrucción de células tumorales. La presente invención también se refiere a métodos para producir las proteínas de unión a antígenos de la invención, así como ácidos nucleicos que las codifican, vectores para y células huésped para su expresión. La invención se refiere además a métodos para tratar o diagnosticar una enfermedad, tal como la leucemia, usando una proteína de unión a antígeno ("ABP", por sus siglas en inglés) FLT3 de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18193889.5A EP3623383A1 (en) | 2018-09-11 | 2018-09-11 | Improved bispecific flt3xcd3 antigen binding proteins |
| EP19189566 | 2019-08-01 | ||
| PCT/EP2019/074268 WO2020053300A1 (en) | 2018-09-11 | 2019-09-11 | Improved anti-flt3 antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002749A true MX2021002749A (es) | 2021-07-16 |
Family
ID=67875473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002749A MX2021002749A (es) | 2018-09-11 | 2019-09-11 | Proteínas de unión al antígeno anti-flt3 mejoradas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220056141A1 (es) |
| EP (1) | EP3850010A1 (es) |
| JP (1) | JP2022500077A (es) |
| KR (1) | KR20210082444A (es) |
| CN (1) | CN113056486A (es) |
| AU (1) | AU2019337394A1 (es) |
| BR (1) | BR112021004686A2 (es) |
| CA (1) | CA3111462A1 (es) |
| IL (1) | IL281351A (es) |
| MX (1) | MX2021002749A (es) |
| PH (1) | PH12021550470A1 (es) |
| SG (1) | SG11202102178PA (es) |
| WO (1) | WO2020053300A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210317216A1 (en) * | 2020-04-14 | 2021-10-14 | Symphogen A/S | Anti-flt3 antibodies and compositions |
| WO2022251695A2 (en) * | 2021-05-28 | 2022-12-01 | Xyone Therapeutics Inc. | Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd) |
| WO2023060277A1 (en) * | 2021-10-08 | 2023-04-13 | Arbele Limited | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof |
| TW202342549A (zh) * | 2022-03-01 | 2023-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｆｌｔ３和ｃｄ３的抗原結合分子及其醫藥用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2682626A1 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
| BR112012015740B1 (pt) | 2009-12-23 | 2020-09-29 | Synimmune Gmbh | Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico |
| LT2794658T (lt) | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| CN109562164B (zh) * | 2016-04-04 | 2022-10-04 | 海默珍科医药有限责任公司 | 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 |
-
2019
- 2019-09-11 CA CA3111462A patent/CA3111462A1/en active Pending
- 2019-09-11 CN CN201980069438.6A patent/CN113056486A/zh active Pending
- 2019-09-11 EP EP19765489.0A patent/EP3850010A1/en active Pending
- 2019-09-11 KR KR1020217010557A patent/KR20210082444A/ko unknown
- 2019-09-11 MX MX2021002749A patent/MX2021002749A/es unknown
- 2019-09-11 JP JP2021537507A patent/JP2022500077A/ja active Pending
- 2019-09-11 SG SG11202102178PA patent/SG11202102178PA/en unknown
- 2019-09-11 US US17/275,647 patent/US20220056141A1/en active Pending
- 2019-09-11 AU AU2019337394A patent/AU2019337394A1/en active Pending
- 2019-09-11 BR BR112021004686-0A patent/BR112021004686A2/pt unknown
- 2019-09-11 WO PCT/EP2019/074268 patent/WO2020053300A1/en active Application Filing
-
2021
- 2021-03-05 PH PH12021550470A patent/PH12021550470A1/en unknown
- 2021-03-09 IL IL281351A patent/IL281351A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3850010A1 (en) | 2021-07-21 |
| JP2022500077A (ja) | 2022-01-04 |
| KR20210082444A (ko) | 2021-07-05 |
| IL281351A (en) | 2021-04-29 |
| PH12021550470A1 (en) | 2021-11-22 |
| WO2020053300A1 (en) | 2020-03-19 |
| BR112021004686A2 (pt) | 2021-06-08 |
| CA3111462A1 (en) | 2020-03-19 |
| US20220056141A1 (en) | 2022-02-24 |
| CN113056486A (zh) | 2021-06-29 |
| SG11202102178PA (en) | 2021-04-29 |
| AU2019337394A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002749A (es) | Proteínas de unión al antígeno anti-flt3 mejoradas. | |
| Tiede et al. | Affimer proteins are versatile and renewable affinity reagents | |
| JP3253966B2 (ja) | 幹細胞増殖因子 | |
| EA202192103A1 (ru) | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) | |
| CN108602854A (zh) | 用于多种癌症免疫治疗的新型肽和肽组合物 | |
| NO20091235L (no) | Antagonistiske humane lysspesifikke monoklonale antistoffer | |
| CN107880128A (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| Meeusen et al. | Secreted tumor antigens–immune biomarkers for diagnosis and therapy | |
| KR20220073738A (ko) | 세포 분류를 위한 기계 학습 방법 | |
| CN101743473A (zh) | 移植物抗宿主疾病的检查及治疗方法 | |
| JP2020527727A (ja) | 診断方法 | |
| Qiu et al. | Use of intercellular proximity labeling to quantify and decipher cell-cell interactions directed by diversified molecular pairs | |
| Erdbrügger et al. | Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers | |
| Fazekas-Singer et al. | AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor | |
| ATE320484T1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
| CN109072192A (zh) | 用于扩展和分化生产抗体的b细胞的方法 | |
| DeVette et al. | A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer | |
| Hernandez‐Fernaud et al. | Quantitative mass spectrometry‐based proteomics in angiogenesis | |
| Yong et al. | Active humoral response reverts tumorigenicity through disruption of key signaling pathway | |
| JP2018188394A (ja) | リン酸化Ｓｍｕｒｆ２を認識する抗体、該抗体を含む癌の診断剤、並びに該抗体を使用した癌の治療剤のスクリーニング方法 | |
| Garetto et al. | Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation | |
| JP2012158534A (ja) | 抗Ｈｅｒ２ヒトモノクローナル抗体 | |
| Umlauf et al. | Identification of brain ECM binding variable lymphocyte receptors using yeast surface display | |
| JP2022545230A (ja) | Ｈｌａ－ａ０２０１拘束性ｋｉｆ１５の特異的抗腫瘍ｃｔｌ優性エピトープペプチド及び応用 |